市场调查报告书
商品编码
1371892
到 2030 年人工关节市场预测:按类型、材料、用途和地区进行全球分析Artificial Joints Market Forecasts to 2030 - Global Analysis By Type (Non Cemented Artificial Joints, Cemented Artificial Joints and Other Types), Material, Application and By Geography |
根据Stratistics MRC的数据,2023年全球人工关节市场规模为215.3亿美元,预计到2030年将达到336.2亿美元,预测期内年复合成长率为6.6%。
关节假体,也称为人工关节或关节移植,是医疗设备。这些设备的设计类似于自然关节,可增加关节活动度、减轻疼痛并恢復身体功能。人工关节经常用于整形外科手术,例如关节重建,以取代因类风湿性关节炎、关节退化和关节外伤等疾病而严重受损的关节。
根据美国国家医学图书馆的数据,到 2022 年,美国全膝关节置换术(TKA) 的需求预计将比 2005 年至 2030 年增加 673%,年度进行 528 万例全膝关节置换术。
提高对关节健康和可用治疗方法的认识并改善患者教育,鼓励个人及时接受医疗干预和关节重建手术。此外,随着世界人口高龄化,骨关节炎和类风湿性关节炎等关节相关疾病的患病不断增加,推动了对关节重建和人工关节的需求。
儘管多年来人工关节已经有所改善,但它们并不是永久的解决方案。大多数人工关节的使用寿命有限,患者可能需要进行翻修手术,这可能既昂贵又乏味。此外,关节重建手术也有其自身的风险,包括感染疾病、血栓和麻醉併发症,这可能会阻止一些患者选择这种手术。
材料、植入物设计和手术技术的不断进步为开发更耐用、更有效率和创新的义肢关节产品提供了机会,这些产品可以改善患者的治疗效果。此外,在预测期内,这些地区对关节重建和人工关节的需求可能会增加,使製造商能够开拓医疗保健需求不断增长的新兴市场。
严格的法规要求和核准流程可能会延迟新义肢产品的推出并增加开发成本。此外,与关节假体相关的不利事件或安全问题的报告可能会削弱患者的信心,并导致对关节假体产品的需求减少。这些限制阻碍了市场的扩张。
由于供应链中断和择期手术延迟,COVID-19 大流行最初扰乱了关节置换市场。然而,随着手术的恢復,市场逐渐復苏,导致手术积压。这种流行病可能会加速远端医疗的采用,影响患者的咨询和后续护理。由于高龄化对人工关节的持续需求以及医疗技术和研究的持续进步,长期预测仍然乐观。
水泥人工关节在 2022 年拥有最大的市场占有率,预计在预测期内将保持其地位。骨水泥关节具有弹性、稳定且牢固地固定在骨骼上。此外,生物相容性高的陶瓷材料和陶瓷含量高的假体关节可以减少关节摩擦和磨损。这些因素在预测期内促进了该领域的成长。
由于膝骨关节炎患病不断上升以及全膝关节关节重建数量不断增加,预计膝关节假体部分在预测期内将出现最高增长。此外,人口高龄化和肥胖率上升等要素患病了骨质疏鬆症和关节炎等与老龄化相关的肌肉骨骼疾病的盛行率,也置换术的主要要素。对外科手术和相应植入物的需求推动了该领域的成长。
预计北美地区将在整个预期期间继续主导市场。该地区最大的两个经济体美国和加拿大是该地区市场价值的主要收益。骨关节炎患者数量的增加和高龄化是推动北美市场扩张需求最高的两个主要因素。此外,由于电脑辅助植入物设计、机器人手术和有利的报销条款的使用增加,预计美国人工关节市场在预测期内将得到提振。
随着膝关节疾病变得更加普遍、医疗旅游蓬勃发展、可支配所得增加以及该地区医疗基础设施的稳步改善,亚太市场将在预测期内快速增长。此外,人口老化和骨关节炎的患病正在增加。骨关节炎患者数量预计将增加,人工关节和关节重建的需求也预计将增加。因此,这些要素预计将推动亚太地区人工关节市场的开拓。
According to Stratistics MRC, the Global Artificial Joints Market is accounted for $21.53 billion in 2023 and is expected to reach $33.62 billion by 2030 growing at a CAGR of 6.6% during the forecast period. Artificial joints, also known as prosthetic joints or joint implants, are medical gadgets designed to replace a human body joint that has been damaged or is aging. These devices are made to function like a natural joint would, enhancing joint mobility, reducing pain, and regaining physical function. Artificial joints are frequently used in orthopedic procedures like joint replacement surgeries to replace joints that have suffered severe damage from diseases like osteoarthritis, rheumatoid arthritis, joint degeneration, or joint trauma.
According to, National Library of Medicine, in 2022, the demand for total knee arthroplasty (TKA) in the U.S. was anticipated to increase 673% from 2005 to 2030, with 5.28 million TKAs to be done annually.
Growing awareness about joint health and available treatment options, as well as improved patient education, encourages individuals to seek timely medical intervention and joint replacement surgeries. Additionally, as the global population continues to age, the prevalence of joint-related conditions like osteoarthritis and rheumatoid arthritis increases, driving the demand for joint replacement surgeries and artificial joints.
While artificial joints have improved over the years, they are not permanent solutions. Most joints have a limited lifespan, and patients may require revision surgeries, which can be costly and complicated. In addition to that joint replacement surgeries come with inherent risks, including infection, blood clots, and anesthesia complications, which can deter some patients from opting for the procedure.
Ongoing advancements in materials, implant design, and surgical techniques offer opportunities for the development of more durable, efficient, and innovative artificial joint products that can improve patient outcomes. Moreover, manufacturers can tap into emerging markets with growing healthcare needs, as these regions may experience increased demand for joint replacement surgeries and artificial joints over the forecast period.
Stringent regulatory requirements and approval processes can delay the introduction of new artificial joint products and increase development costs. In addition, reports of adverse events or safety concerns related to artificial joints can erode patient trust and lead to reduced demand for these products. Such limitations hinder the market expansion.
The COVID-19 pandemic initially disrupted the artificial joints market due to supply chain disruptions and postponed elective surgeries. However, the market rebounded as surgeries resumed, creating a backlog of procedures. The pandemic accelerated the adoption of telehealth, potentially impacting patient consultations and follow-up care. Long-term prospects remain positive due to an aging population's sustained demand for joint replacements, coupled with ongoing advancements in medical technology and research.
The market's largest share was held by the cemented joints segment in 2022, and it is anticipated that it will hold that position throughout the forecast period. Joints made of cement are more elastic, stable, and securely attached to the bones. Additionally, biocompatible ceramic materials and artificial joints with a high ceramic content can lessen joint friction and wear. Such elements contribute to the segment's growth over the course of the forecast period.
Due to the rising prevalence of knee osteoarthritis and the rising number of knee replacement surgeries, the artificial knee joint segment is anticipated to experience the highest growth over the course of the forecast period. In addition, factors like the aging population, which is increasing the prevalence of age-related musculoskeletal conditions like osteoporosis and arthritis, and the rising obesity rate are all significant drivers of the demand for knee and hip replacement surgeries and the corresponding implants, which is boosting the segment's growth.
The North American region is expected to continue to dominate the market throughout the anticipated period. The two largest economies in the area, the U.S. and Canada, are the main revenue generators for the market value in the area. An increase in osteoarthritis patients and an aging population are the two primary factors that are most likely to increase demand for market expansion in North America. Additionally, it is anticipated that the U.S. artificial joints market will be fueled by an increase in the use of computer-aided implant designs, robotic surgery, and favorable reimbursement conditions over the course of the projection period.
As knee disorders are becoming more prevalent, medical tourism is booming, disposable income is rising, and the healthcare infrastructure in this region is steadily improving, the Asia Pacific market is predicted to grow quickly over the forecasted period. Additionally, there is a rise in geriatric populations and osteoarthritis prevalence. The number of people with osteoarthritis is expected to rise, as will the demand for artificial joints and arthroplasty surgeries. Thus, it is anticipated that these factors will fuel the development of the artificial joint market in Asia-Pacific.
Some of the key players in Artificial Joints market include: Zimmer Biomet Holding Inc, Conformis Inc, Smith & Nephew plc, Stryker Corporation, B. Braun Melsungen AG, Medtronic plc, Johnson and Johnson, Exactech, Medacta International SA and MicroPort Orthopedics Inc.
In June 2023, BioMed X has announced that it has begun a joint research project with Sanofi on artificial intelligence (AI)-driven drug development. The two companies initially announced their partnership late last year, and are now ready to begin work on their AI drug discovery platform. The "Next Generation Virtual Patient Engine for Clinical Translation of Drug Candidates" (VPE) project aims to develop a computational platform capable of predicting the efficacy of first or best-in-class drug candidates.
In August 2023, Corentec, a company specializing in the production of artificial joints, announced that the inaugural surgery involving its patient-specific implant (PSI) designed for artificial shoulder joints was effectively carried out at Kyungpook National University Hospital in Korea.